PHIO vs. ICAD

Last updated Jun 3, 2026

PHIO (Phio Pharmaceuticals Corp.) and ICAD (iCAD, Inc.) are both stocks. Both are in the Healthcare sector — PHIO in Biotechnology, ICAD in Health Information Services. At a 0.12 correlation, their price movements are largely independent.

Performance

PHIO vs. ICAD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Phio Pharmaceuticals Corp. (PHIO) and iCAD, Inc. (ICAD). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

PHIO

• 1D: -0.88%
• 1M: -1.75%
• YTD: 6.67%
• 6M: -8.94%
• 1Y: -45.37%
• 3Y*: -66.60%
• 5Y*: -65.65%
• 10Y*: -68.82%

ICAD

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

PHIO vs. ICAD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PHIO Phio Pharmaceuticals Corp.	6.67%	-41.67%	-73.68%	-82.97%	-62.80%	-62.83%	-71.40%	-48.17%	-94.07%	-22.21%
ICAD iCAD, Inc.	0.00%	111.48%	3.39%	-3.28%	-74.58%	-45.45%	69.88%	110.00%	7.56%	6.34%

Correlation

The correlation between PHIO and ICAD is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.11
Correlation (5Y) Calculated over the trailing 5-year period	0.12
Correlation (10Y) Calculated over the trailing 10-year period	0.13
Correlation (All Time) Calculated using the full available price history since May 11, 2012	0.12

Fundamentals

Total Revenue (TTM) PHIO : $0.00 ICAD : $19.53M
Gross Profit (TTM) PHIO : -$1.08M ICAD : $16.77M
EBITDA (TTM) PHIO : -$7.23M ICAD : -$4.84M

Return for Risk

PHIO vs. ICAD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PHIO

PHIO Risk / Return Rank: 20
PHIO Sharpe Ratio Rank: 18
PHIO Sortino Ratio Rank: 20
PHIO Omega Ratio Rank: 21
PHIO Calmar Ratio Rank: 18
PHIO Martin Ratio Rank: 22

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PHIO vs. ICAD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Phio Pharmaceuticals Corp. (PHIO) and iCAD, Inc. (ICAD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PHIO	ICAD	Difference
Sharpe ratio Return per unit of total volatility	-0.53	—	—
Sortino ratio Return per unit of downside risk	-0.46	—	—
Omega ratio Gain probability vs. loss probability	0.95	—	—
Calmar ratio Return relative to maximum drawdown	-0.62	—	—
Martin ratio Return relative to average drawdown	-0.91	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	PHIO	ICAD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.53	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.36	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.46	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.25	—	—

Drawdowns

Drawdown Indicators

	PHIO	ICAD	Difference
Max Drawdown Largest peak-to-trough decline	-100.00%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-71.05%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-97.15%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-99.67%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-100.00%	—	—
Current Drawdown Current decline from peak	-100.00%	—	—
Average Drawdown Average peak-to-trough decline	-91.33%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	48.14%	—	—

Volatility

Volatility by Period

	PHIO	ICAD	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.39%	—	—
Volatility (6M) Calculated over the trailing 6-month period	64.55%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	86.33%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	183.79%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	150.20%	—	—

Dividends

PHIO vs. ICAD - Dividend Comparison

Neither PHIO nor ICAD has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both PHIO and ICAD in my portfolio?

PHIO and ICAD have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.